BioRestorative issued 3 patents for stem cell platform

By The Science Advisory Board staff writers

March 22, 2021 -- BioRestorative Therapies has been issued three separate patents related to the company's metabolic ThermoStem stem cell program.

The patents relate to a specific isolated stem cell derived from human brown adipose tissue that's capable of differentiating into multiple cell types. These cells have potential therapeutic uses for treating a wide range of degenerative and metabolic disorders.

The ThermoStem platform technology can be used to develop cell-based therapy candidates that mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.

The notices of allowances cover the U.S., Israel, France, Germany, Italy, Spain, and the U.K. The applications have been issued or are expected to issue as patents in 2021.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.